UFPTMEDIUM SIGNALOPERATIONAL10-K

UFPT has strategically refocused its business positioning from a broad "designer and custom manufacturer" to a specialized "contract development and manufacturing organization" concentrated exclusively on single-use medical devices.

The refined business description signals a strategic pivot toward higher-margin CDMO services while eliminating references to automotive markets, suggesting management is concentrating resources on their core medical device competency. This focused positioning typically commands premium pricing and stronger customer relationships but reduces diversification across end markets.

Comparing 2026-02-27 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

UFPT delivered solid operational performance with revenue growing 19.5% to $603M and net income advancing 15.8% to $68M, while operating cash flow expanded meaningfully to $92M. The company strengthened its balance sheet considerably, reducing total debt by 28.5% to $136M while cash increased substantially to $20M, resulting in stockholders' equity growth of 24% to $424M. The financial profile reflects a company successfully scaling its operations while deleveraging and building financial flexibility.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+50.9%
$13.4M→$20.3M

Cash position surged 50.9% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
+38%
$66.6M→$91.9M

Operating cash flow surged 38% — exceptional cash generation, highest quality earnings signal.

Total Debt
Balance Sheet
-28.5%
$189.4M→$135.5M

Debt reduced 28.5% — deleveraging strengthens balance sheet and reduces financial risk.

SG&A Expense
P&L
+24.5%
$62.2M→$77.4M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Stockholders Equity
Balance Sheet
+23.7%
$342.8M→$423.9M

Equity base grew 23.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
+19.5%
$504.4M→$602.8M

Revenue growing 19.5% — solid top-line momentum, watch margins for quality of growth.

Total Liabilities
Balance Sheet
-19.2%
$286.2M→$231.2M

Liabilities reduced 19.2% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-17.3%
$10.4M→$8.6M

R&D spending cut 17.3% — could signal cost discipline or concerning reduction in innovation investment.

Gross Profit
P&L
+16.2%
$146.7M→$170.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Net Income
P&L
+15.8%
$59.0M→$68.3M

Net income grew 15.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-03
ADDED
As of February 19, 2026, there were 7,713,300 shares of common stock, $0.01 par value per share, of the registrant outstanding.
BUSINESS The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices.
The Company is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers.
Our single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.
and its wholly owned subsidiaries, as well as its share of minority-owned equity investments.
+7 more — sign up free →
REMOVED
As of February 25, 2025, there were 7,680,305 shares of common stock, $0.01 par value per share, of the registrant outstanding.
BUSINESS The Company is a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products.
The Company believes it is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world.
The Company s single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, robotic surgery, patient handling, orthopedic implants, wound care, wearables, and orthopedic soft goods.
The Company sells its products into distinct markets with its primary focus on the MedTech market: MedTech The global medical market is large and growing but the Company targets in specific segments where its development and manufacturing expertise and access to highly specialized materials helps customers differentiate products, improve patient outcomes, and increase their client s speed to market.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →